Dutch Competition Body Urged To Fine Leadiant Over 'Exorbitant' Orphan Drug Price

The Dutch Pharmaceutical Accountability Foundation has asked the country's competition authority to take action against Leadiant Biosciences over the company's pricing of an orphan drug for a rare genetic disease.